These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12090039)

  • 21. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus.
    Li D; Dragan Y; Jordan VC; Wang M; Pitot HC
    Cancer Res; 1997 Apr; 57(8):1438-41. PubMed ID: 9108442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.
    Hayes DF; Van Zyl JA; Hacking A; Goedhals L; Bezwoda WR; Mailliard JA; Jones SE; Vogel CL; Berris RF; Shemano I
    J Clin Oncol; 1995 Oct; 13(10):2556-66. PubMed ID: 7595707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Phase I study of NK 622 (toremifene citrate)].
    Tominaga T; Hayashi K; Hayasaka A; Asaishi K; Abe R; Kimishima I; Izuo M; Iino Y; Yokoe T; Abe O
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2363-72. PubMed ID: 1463343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
    Goss P; Bondarenko IN; Manikhas GN; Pendergrass KB; Miller WH; Langecker P; Blanchett D
    J Clin Oncol; 2007 Nov; 25(31):4961-6. PubMed ID: 17971594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment].
    Niikura N; Kimura M; Kobayashi Y; Asahara F; Hayashi K; Shibata S; Shintoku J
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):1013-6. PubMed ID: 19542727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women.
    Furlanut M; Franceschi L; Pasqual E; Bacchetti S; Poz D; Giorda G; Cagol P
    Ther Drug Monit; 2007 Jun; 29(3):349-52. PubMed ID: 17529893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.
    Hong J; Huang J; Shen L; Zhu S; Gao W; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
    BMC Cancer; 2020 Jul; 20(1):663. PubMed ID: 32677982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recent development of endocrine treatment for breast cancer--new drugs and new treatment methods using tamoxifen].
    Sonoo H; Kurebayashi J
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2289-99. PubMed ID: 8259841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.
    Ishiguro H; Ohno S; Yamamoto Y; Takao S; Sato N; Fujisawa T; Kadoya T; Kuroi K; Bando H; Teramura Y; Iwata H; Tanaka S; Toi M
    Breast Cancer; 2019 Sep; 26(5):535-543. PubMed ID: 30734152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA].
    Sonoo H; Senoo T; Nishiki M; Morimoto T; Takashima S
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Breast cancer--tamoxifen and tamoxifen analogues for the treatment of breast cancer].
    Iino Y; Morishita Y
    Nihon Rinsho; 1994 Mar; 52(3):797-803. PubMed ID: 8164385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen modulates the expression of Ki67, apoptosis, and microvessel density in cervical cancer.
    Ferrandina G; Ranelletti FO; Larocca LM; Maggiano N; Fruscella E; Legge F; Santeusanio G; Bombonati A; Mancuso S; Scambia G
    Clin Cancer Res; 2001 Sep; 7(9):2656-61. PubMed ID: 11555576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer].
    Koyama H; Iesato A; Fukushima Y; Okada T; Watanabe T; Harada M; Ito T; Maeno K; Mochizuki Y; Ito K; Amano J
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1123-6. PubMed ID: 21772095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin.
    Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Cancer Chemother Pharmacol; 2008 May; 61(6):933-41. PubMed ID: 17668211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B].
    Mitsuyama S; Nomura Y; Ohno S; Miyauchi M; Yamamoto N; Kimura T; Saku M; Miura S; Yoshikawa N; Tsujinaka T; Koh J; Ishida T; Abe O; Ohashi Y
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2071-7. PubMed ID: 16352931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
    Sakurai K; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2246-8. PubMed ID: 21224536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A breast cancer patient with recurrence in the thoracic wall in whom a high-dose of toremifene was effective].
    Ishida K; Mori H; Fujii T; Kawashima K; Hanaoka T; Mihara Y
    Gan To Kagaku Ryoho; 2001 Feb; 28(2):225-8. PubMed ID: 11242651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer].
    Zhang J; Zhang JH; Liu Y; Hao XM; Fang ZX; Li SL
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(46):3268-71. PubMed ID: 18396622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.